sesn-20220617

0001485003-22-000075.txt : 20220617 0001485003-22-000075.hdr.sgml : 20220617 20220617080047 ACCESSION NUMBER: 0001485003-22-000075 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220617 ITEM INFORMATION: Other Events FILED AS OF DATE: 20220617 DATE AS OF CHANGE: 20220617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 221022414 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 8-K 1 sesn-20220617.htm 8-K sesn-20220617

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17 , 2022

SESEN BIO, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36296

26-2025616

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

245 First Street, Suite 1800

Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 444-8550

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)


☐			Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))


☐			Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	SESN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 – Other Events.

On June 17, 2022, Sesen Bio, Inc. (the “Company”) announced that it has removed the proposal to approve an amendment to the Company’s Restated Certificate of Incorporation, to effect a reverse stock split of the Company’s common stock and a proportionate reduction in the number of authorized shares of common stock (“Proposal 2”) as further described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2022 (the “Proxy Statement”), from the agenda for its Annual Meeting of Stockholders (“Annual Meeting”) to be held on June 22, 2022.

As previously disclosed, the Company has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy. The Company is confident in its ability to maximize shareholder value without effecting a reverse stock split at this time. The Company will continue to monitor the situation and will consider options to regain compliance with the Nasdaq’s minimum bid price as needed.

No additional changes have been made to the Proxy Statement or the record date, the location of the meeting or the other proposals to be brought before the 2022 Annual Meeting, which were disclosed in the Proxy Statement. The Company will not distribute, and you do not need to sign, new proxy cards or submit new voting instructions solely as a result of the withdrawal of Proposal 2. Any proxy card or voting instructions received in the future for Proposals 1, 3, and 4 will be valid. If you already submitted a proxy card or voting instructions, you do not need to resubmit proxies or voting instructions with different directions, unless you wish to change votes previously cast on the remaining proposals.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Company’s plans to continue its development activities in accordance with its existing business strategy pending any decision to undertake any strategic alternative, the Company’s ability to maximize shareholder value without effecting a reverse stock split at this time, the Company’s plans to continue to monitor the situation and the Company’s plans to consider options to regain compliance with the Nasdaq’s minimum bid price as needed, which are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not be able to regain compliance with the minimum bid price requirement for continued listing on Nasdaq, the risk that the Company may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 17, 2022



Sesen Bio, Inc.

By:						/s/ Thomas R. Cannell, D.V.M.
						Thomas R. Cannell, D.V.M.
						President and Chief Executive Officer

EX-101.SCH 2 sesn-20220617.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sesn-20220617_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 4 sesn-20220617_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 17, 2022
Cover [Abstract]
Document Type	8-K
Entity Registrant Name	SESEN BIO, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-36296
Entity Tax Identification Number	26-2025616
Entity Address, Address Line One	245 First Street
Entity Address, Address Line Two	Suite 1800
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	617
Local Phone Number	444-8550
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	SESN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001485003
Amendment Flag	false
Document Period End Date	Jun. 17, 2022

XML 6 sesn-20220617_htm.xml IDEA: XBRL DOCUMENT 0001485003 2022-06-17 2022-06-17 false 0001485003 8-K 2022-06-17 SESEN BIO, INC. DE 001-36296 26-2025616 245 First Street Suite 1800 Cambridge MA 02142 617 444-8550 false false false false Common Stock, par value $0.001 SESN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.sesenbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sesn-20220617.htm sesn-20220617.xsd sesn-20220617_lab.xml sesn-20220617_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sesn-20220617.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sesn-20220617.htm" ] }, "labelLink": { "local": [ "sesn-20220617_lab.xml" ] }, "presentationLink": { "local": [ "sesn-20220617_pre.xml" ] }, "schema": { "local": [ "sesn-20220617.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sesn", "nsuri": "http://www.sesenbio.com/20220617", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sesn-20220617.htm", "contextRef": "if764b780f0ba43e98960a5f7d9ea57af_D20220617-20220617", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.sesenbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sesn-20220617.htm", "contextRef": "if764b780f0ba43e98960a5f7d9ea57af_D20220617-20220617", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.sesenbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001485003-22-000075-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001485003-22-000075-xbrl.zip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